Melanoma
Cancer Journey

Welcome Home Sidebar Block

 

 

VIDEO LIBRARIES

Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal 1st line treatment for a patient with advanced non squamous non small cell lung cancer, high PD-L1, and no driver mutation.

Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss if there is a best systemic therapy option for a patient with advanced non-squamous NSCLC, low PD-L1 and no driver mutation.

Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal approach for a fit patient with advanced squamous NSCLC and low tumor PD-L1 expression.

Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the treatment choice between targeted therapy and immunotherapy in a patient with an EGFR Mutation and high PDL-1.

Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss a frail patient with metastatic squamous NSCLC with low tumor PD-L1 expression, and the best treatment approach for this patient.

ARTICLES

There were many advances in lung cancer targeted treatments in 2014. The one that most excites Dr. Geoffrey Oxnard from Dana-Farber Cancer Institute...

An annual tradition is a reflection on the key developments in the field over the past year. This year saw some major advances, with several of the...

It may not be the biggest present lung cancer patients could get for the holiday season, but the FDA just yesterday approved Cyramza (ramucirimab), an...

I have lived with lung cancer since 2005. On this "Giving Tuesday," I ask that you join me in making an end-of-year donation to an organization that...

Linnea Duff, a 10-year stage IV ALK+ lung cancer patient, gives thanks to GRACE and urges others to do the same. Watch, read, and then share your own...

COMMUNITY FORUM

What does mutational burden mean? As one goes through from one effective treatment to another to another over time, does one's the mutation burden...
Hello, I have alk + Stage IV NSCLC since 2008. Five years ago I went on Brigatinib for asymptomatic brain mets with great results. In Jan, several...
I have NSCLC EFGR exon 19 deletion and had 2 VATS, Tarceva and have been on Tagrisso for over 20 months. I have been on a two week break because of...

Ketki Patel, a Patient Financial Advocate in Seattle recently offered suggestions and helpful information for financial navigation during your cancer...

Many types of treatments have been FDA approved for lung cancer that focused on different approaches. For examples: Targeted therapies for Alk and...
Subscribe to Melanoma